文献速递皮肤肿瘤

转移性黑色素瘤患者免疫治疗后恢复生活的体验及相关生存照护需求:一项定性研究

Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
PubMed 文献 · Br J Dermatol · 2022-06-14

该定性研究纳入20例转移性黑色素瘤患者,均在免疫检查点抑制剂(ICI)治疗获得持续肿瘤缓解后停药,通过1个焦点小组(n=9)和11例个体访谈,采用主题内容分析探讨其恢复生活的体验及生存照护(SSC)需求。患者面临预后转变的不确定感、自我与他人期望、持续主诉及新问题等挑战,需寻找新平衡;SSC需求包括更个性化的患者信息、单一联络点、心理社会支持(含亲属)。作者认为应在诊断起即提供心理社会支持,并考虑单一联络点和个性化生存照护计划(SCP)的附加价值。

要点

  • ICI停药后持续缓解的转移性黑色素瘤患者恢复生活时面临预后不确定感、持续主诉和新问题等挑战。
  • 患者需寻找新平衡,包括学习应对不确定性和对生活及亲密关系看法的改变。
  • SSC需求包括更个性化的患者信息(可在一个地点获取)、知道有疑问时找谁及心理社会支持(含亲属)。

核心结论

  • 转移性黑色素瘤幸存者在ICI后恢复生活面临各种挑战,并存在多项未满足的SSC需求。
  • 作者认为应自诊断起在医疗照护之外提供心理社会支持性照护,并考虑患者亲属。
  • 作者认为单一联络点和个性化生存照护计划(SCP)可能具有附加价值,鉴于黑色素瘤照护的多学科性质,后者尤为重要。

研究设计与样本

  • 在20例ICI停药后持续肿瘤缓解的转移性黑色素瘤患者中开展定性研究。
  • 举办1个焦点小组(n=9),并补充11例个体访谈。
  • 采用目的性抽样,按性别、年龄、ICI停药后时间及感知疾病影响选取多样样本。
  • 使用主题指南结构化(小组)访谈,访谈逐字转录并采用主题内容分析,经过多个编码阶段。

主要发现

  • 恢复生活时,预后转变常引起患者复杂感受,主要因对未来的不确定性。
  • 来自自我与他人的要求和期望、持续主诉及不同生活领域的新问题常使患者难以如转移性癌症前那样继续生活。
  • 患者表示需要寻找新平衡,包括学习应对不确定性和对生活及亲密关系看法的改变。
  • SSC需求方面,患者特别强调需要更个性化的患者信息并可在单一地点获取。
  • 患者强调需要知道有疑问时向谁求助,并指出需要心理社会支持,也包括对其亲属的支持。

临床怎么用

  • 作者认为除医疗照护外,应自诊断起关注提供心理社会支持性照护,包括重返工作问题,并理想地考虑患者亲属。
  • 作者认为单一联络点和个性化生存照护计划(SCP)可能有助于指导患者走过诊疗旅程。
  • 作者认为鉴于黑色素瘤照护的多学科性质,个性化SCP在黑色素瘤照护中尤为重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved the overall survival of patients with metastatic melanoma. It is unclear how the growing group of metastatic melanoma survivors resume their lives after treatment, and which needs they have regarding survivorship care (SSC). OBJECTIVES: To gain an in-depth understanding of metastatic melanoma survivors' experiences of resuming life after ICIs and their associated SSC needs. METHODS: A qualitative study was conducted among 20 patients with metastatic melanoma in whom ICIs had been discontinued after ongoing tumour response. One focus group (n = 9) was held, which was complemented by 11 individual interviews. Purposive sampling was used to select a variable sample in terms of sex, age, time since discontinuation of ICIs, and perceived impact of the disease. A topic guide was used to structure the (group) interviews, which were transcribed verbatim and analysed in a thematic content analysis, using several phases of coding. RESULTS: In resuming life after ICIs, the prognosis switch often caused mixed feelings among patients, mainly because of the uncertainty about the future. Demands and expectations from self and others, persistent complaints and new problems in different life domains often make it challenging to proceed with life as it was prior to metastatic cancer. Patients indicated they needed to find a new balance, which included learning to cope with uncertainty and a changed perspective on life and close relationships. In terms of SSC needs, patients particularly stressed the need for more tailored patient information, available at one location. In addition, they emphasized the need to know who to turn to in case of questions and indicated the need for psychosocial support, also for their close relatives. CONCLUSIONS: Metastatic melanoma survivors face various challenges in resuming life after ICIs and are left with several unmet SSC needs. Efforts should be focused on offering psychosocial supportive care in addition to medical care, from diagnosis onwards, taking into account the patient's close relatives. A single point of contact and personalized survivorship care plan (SCP) could be of added value in guiding them through the patient journey, which is, given its multidisciplinary nature, particularly important in melanoma care. What is already known about this topic? Since the introduction of immune checkpoint inhibitors (ICIs) the overall survival of patients with metastatic melanoma has improved significantly, leading to a growing group of melanoma survivors. Melanoma survivors may face various problems and challenges in resuming life after treatment, which may be associated with unmet survivorship care (SSC) needs. An in-depth understanding of their experiences with resuming life and the associated SSC needs is currently lacking. What does this study add? Metastatic melanoma survivors experience various challenges after immunotherapy, from the uncertain prognosis switch to the struggle of finding a new balance in life. Besides negative aspects, such as complaints in different life domains, the patient journey is often accompanied by positive outcomes, for example a changed perspective on life. They stress the need for tailored patient information and broader supportive care, also for their close relatives. What are the clinical implications of this work? In addition to medical care, efforts should be focused on offering psychosocial supportive care, including return-to-work issues, from diagnosis onwards, ideally taking into account the patient's close relatives. To guide them through the patient journey, a single point of contact and a personalized survivorship care plan (SCP) could be of added value. The latter is particularly important in melanoma care, given its multidisciplinary nature.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kamminga NCW, van der Veldt AAM, Joosen MCW, et al. Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. Br J Dermatol. 2022. PMID: 35596713. doi:10.1111/bjd.21670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。